1. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Issue 9 (September 2022) Authors: Pierce, Glenn F; Adediran, Megan; Diop, Saliou; Dunn, Amy L; El Ekiaby, Magdy; Kaczmarek, Radoslaw; Konkle, Barbara A; Pipe, Steven W; Skinner, Mark W; Valentino, Leonard A; Robinson, Fiona; Ampartzidis, Georgios; Martin, Jayson; Haffar, Assad Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia. (2nd September 2022) Authors: Segurado, Oscar G; Jiang, Ruhong; Pipe, Steven W Journal: Expert opinion on biological therapy Issue: Volume 22:Number 9(2022) Page Start: 1091 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comparison of Activated Protein C Resistance With Factor V Leiden Testing by Molecular Assay. (11th September 2019) Authors: Perry, William R; Pipe, Steven W; Li, Shih-Hon Journal: American journal of clinical pathology Issue: Volume 152(2019)Supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Issue 10274 (13th February 2021) Authors: Mancuso, Maria Elisa; Mahlangu, Johnny N; Pipe, Steven W Journal: Lancet Issue: Volume 397:Issue 10274(2021) Page Start: 630 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗